NCT05530421

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

Conditions

• Relapsed and Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Selinexor	Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
DRUG	Venetoclax	Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
DRUG	Dexamethasone	Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

Timeline

• Start date: 2023-03-26
• Primary completion: 2028-03-26
• Completion: 2030-03-26
• First posted: 2022-09-07
• Last updated: 2026-02-23

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study